For the quarter ending 2025-06-30, TSBX had -$10,448K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation expense | 593 |
| Prepaid expenses | -2,825 |
| Other current assets | -1,277 |
| Operating lease liabilities | -110 |
| Accounts payable | 1,817 |
| Loss on disposal of property and equipment | -2,564 |
| Depreciation and amortization | 301 |
| Change in fair value of contingent consideration liability | -92 |
| Accrued compensation and other accrued liabilities | -3,274 |
| Net cash flows used in operating activities | -11,395 |
| Proceeds from sale of property and equipment | 947 |
| Net cash flows provided by investing activities | 947 |
| Net decrease in cash, cash equivalents and restricted cash | -10,448 |
Turnstone Biologics Corp. (TSBX)
Turnstone Biologics Corp. (TSBX)